Artiva’s President and CEO Fred Aslan, M.D., explores how Artiva is reshaping cell therapy with In Vivo. In the maturing landscape of cell therapy, Artiva Biotherapeutics stands out for its unique approach: using un-engineered natural killer (NK) cells for oncologic and immune indications.
Read the full article here (subscription may be required).
In this interview with Pharmaceutical Manufacturer, Artiva CEO Fred Aslan, M.D., discusses the unique advantages of natural killer (NK) cell therapies and the company’s mission to bring scalable, off-the-shelf treatments to patients with autoimmune diseases. The Q&A explores how Artiva’s AlloNK® platform—comprising non-genetically modified, cryopreserved NK cells combined with disease-targeting monoclonal antibodies—could offer a more...
In a new feature published by GEN (Genetic Engineering & Biotechnology News), natural killer (NK) cells are in the spotlight showcasing their potential as the next generation of immunotherapies. This article explores how scientific and technological advances are helping cell therapy developers harness NK cells to expand the reach of cell therapy beyond oncology and...
NK cells, part of the innate immune system, serve as the body’s first line of defense. These cells can recognize and kill abnormal or infected cells. As therapies, they have the advantage over CAR-T and other cell therapies because they can be used off-the-shelf without undergoing gene editing or other genetic modifications. They also don’t...